U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07659782) titled 'A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer' on June 15.
Brief Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: VS-7375
Taken by mouth
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Verastem, Inc.
Disclaimer: Curated by HT Syndication....